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 2 
Abstract 32 
Introduction: Although HIV infection and its associated co-morbidities remain the 33 
commonest reason for hospitalisation in Africa, their impact on economic costs and 34 
health-related quality of life (HRQoL) are not well understood. This information is 35 
essential for decision-makers to make informed choices about how to best scale-up anti-36 
retroviral treatment (ART) programmes. This study aimed to quantify the impact of 37 
HIV infection and ART on economic outcomes in a prospective cohort of hospitalised 38 
patients with high HIV prevalence. 39 
 40 
Methods: Sequential medical admissions to Queen Elizabeth Central Hospital, Malawi, 41 
between June-December 2014 were followed until discharge, with standardised 42 
classification of medical diagnosis and estimation of healthcare resources used. Primary 43 
costing studies estimated total health provider cost by medical diagnosis. Participants 44 
were interviewed to establish direct non-medical and indirect costs. Costs were adjusted 45 
to 2014 US$ and INT$. HRQoL was measured using the EuroQol EQ-5D. 46 
Multivariable analyses estimated predictors of economic outcomes. 47 
 48 
Results: Of 892 eligible participants, 80.4% (647/892) were recruited and medical 49 
notes found. In total, 447/647 (69.1%) participants were HIV-positive, 339/447 50 
(75.8%) were on ART prior to admission, and 134/647 (20.7%) died in hospital. Mean 51 
duration of admission for HIV-positive participants not on ART and HIV-positive 52 
participants on ART was 15.0 days (95%CI: 12.0-18.0) and 12.2 days (95%CI: 10.8-53 
13.7) respectively, compared to 10.8 days (95%CI: 8.8-12.8) for HIV-negative 54 
participants. Mean total provider cost per hospital admission was US$74.78 (bootstrap 55 
95%CI: US$25.41-US$124.15) higher for HIV-positive than HIV-negative participants. 56 
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Amongst HIV-positive participants, the mean total provider cost was US$106.87 57 
(bootstrap 95%CI: US$25.09-US$106.87) lower for those on ART than for those not 58 
on ART. The mean total direct non-medical and indirect cost per hospital admission 59 
was US$87.84. EQ-5D utility scores were lower amongst HIV-positive participants, 60 
but not significantly different between those on and not on ART.  61 
 62 
Conclusions: HIV-related hospital care poses substantial financial burdens on health 63 
systems and patients; however, per-admission costs are substantially lower for those 64 
already initiated onto ART prior to admission. These potential cost savings could offset 65 
some of the additional resources needed to provide universal access to ART.  66 
 4 
Introduction 67 
In Eastern and Southern Africa, HIV infection and its associated co-morbidities remain 68 
the most common reasons for hospitalisation [1-3]. Up to three quarters of adults 69 
admitted for medical reasons are HIV-positive [2], with little change observed since the 70 
scale-up of anti-retroviral treatment (ART) began [4, 5]. Hospitals account for a major 71 
proportion of health expenditure in the region [6] and reducing the need for hospital 72 
care could lead to major cost savings for health systems. However, without a clear 73 
understanding of the costs of providing hospital care for people living with HIV, and 74 
how this changes with ART [7], decision-makers across the region are unable to include 75 
these potential cost savings in assessments of the cost of scaling up ART.  76 
 77 
In resource-rich countries, timely initiation of ART in HIV-positive individuals has 78 
substantially reduced the need for hospital care and, consequently, the costs of 79 
providing HIV care [8, 9]. In Africa, initiation of ART reduces rates and duration of 80 
hospitalisations in HIV-positive individuals by up to 70% [10-12], but the degree to 81 
which this translates into cost savings for healthcare providers is still uncertain [7]. 82 
Timely initiation of ART reduces the risk of opportunistic and TB disease [13], but 83 
HIV-positive individuals on ART may still need hospital care, and individuals may 84 
incur greater costs during their hospitalisation than those not receiving ART, possibly 85 
as a consequence of developing immune constitution syndrome (IRS) [11, 14]. As we 86 
move towards immediate initiation of ART for HIV-positive individuals [15], the 87 
combined reduction in the risk of developing TB, IRS and other opportunistic illnesses 88 
may translate into cost savings. Understanding the impact of timely initiation of ART 89 
on the wider health system, especially hospital care, will be essential for budgetary and 90 
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service planning, and for informing economic evaluations of HIV prevention and 91 
treatment interventions.  92 
 93 
In this study, we recruited a cohort of adults admitted to the medical wards at Queen 94 
Elizabeth Hospital in Blantyre, Malawi. The main aim was to quantify the impact of 95 
HIV infection and ART on economic outcomes for adults admitted to these medical 96 
wards.   97 
 98 
 99 
Methods 100 
Study design and participants 101 
We undertook a prospective cohort study in Queen Elizabeth Central Hospital (QECH), 102 
Blantyre, Malawi, between June and December 2014. We collected medical diagnosis 103 
and resource use data, and undertook primary resource-based costing studies to estimate 104 
health provider costs. We also investigated the costs incurred by patients and their 105 
families as a result of hospitalisation, and evaluated their health-related quality of life 106 
(HRQoL) on admission and at regular time intervals thereafter.  107 
 108 
QECH is the largest hospital in Malawi, with approximately 1,500 beds and 25,000 109 
adult admissions per year, and an HIV prevalence of approximately 70% amongst 110 
medical inpatients [16]. The hospital has a large emergency department where all new 111 
patients are triaged and assessed by medical doctors or clinical officers. Clinicians 112 
make a preliminary medical diagnosis, and those in need of admission are transferred 113 
to one of three medical wards (Male Medical; Female Medical; TB Ward).  114 
 115 
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Systematic recruitment was used to select every fifth adult (age ≥ 18 years) admission 116 
from each of the three ward registers, together with all adults diagnosed with an AIDS 117 
defining illness on admission. Participants were approached for informed consent on 118 
the first working day after admission. Participants too sick to provide consent were 119 
reviewed daily.  120 
 121 
A structured questionnaire was used to collect data on the first working day after 122 
admission, including socio-demographic data, direct non-medical costs and indirect 123 
costs associated with the admission, and health-related quality of life (HRQoL) 124 
outcomes. Follow-up questionnaires were administered to participants every three to 125 
seven days thereafter, and recorded direct non-medical and indirect costs for the 126 
preceding day, and HRQoL on the day of assessment. After discharge or death, a trained 127 
study doctor extracted data from the medical notes and drug charts. Primary costing 128 
studies were undertaken to estimate direct health provider costs of each hospital 129 
admission episode [17, 18]. 130 
 131 
Ethical approval was obtained from the College of Medicine Ethics Review Committee 132 
(P.08/12/1272), University of Malawi, and the University of Warwick Biomedical 133 
Research Ethics Committee (REGO-2013-061). All participants provided written (or 134 
witnessed thumbprint if illiterate) informed consent. 135 
  136 
Medical diagnosis and resource-use 137 
Data extraction tools and codebooks were developed and piloted to extract the 138 
following data from the medical notes: primary medical diagnosis upon discharge or 139 
death, HIV status, anti-retroviral drug use, duration of hospital admission, types and 140 
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numbers of investigations and procedures performed, medications given, and the 141 
participant’s outcome (discharged; transferred to another hospital; or died). Coding of 142 
the final medical diagnosis upon discharge or death was based on International 143 
Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) [19]. Only 144 
the primary medical diagnosis that necessitated hospital admission was recorded.  145 
 146 
During this study, Malawian national guidelines recommended HIV testing and 147 
counselling for all individuals attending or admitted to a health facility, and ART to 148 
those who meet eligibility criteria (CD4 count <350 cells/μl; WHO stage 3 or 4; 149 
breastfeeding or pregnant). Since August 2016, Malawi has been offering ART to all 150 
HIV-positive individuals irrespective of HIV disease stage.  151 
 152 
Direct health provider cost 153 
We identified a list of medical resource inputs (e.g. days of admission; full blood count) 154 
from the medical data extracted by the doctors, and then undertook accounting studies 155 
to estimate the unit costs for each resource input, and subsequently the total direct 156 
health provider cost. For each resource input, we included the cost of: staff salaries; 157 
training of staff; consumables and equipment; monitoring and evaluation; and 158 
associated overheads. Appendix A provides a detailed description of the costing 159 
processes, and how the total direct health provider cost was estimated. The 160 
international market price was used for the cost of drugs [20].  161 
 162 
Direct non-medical and indirect cost 163 
The development, language translations and pilot testing of participant questionnaires 164 
followed previous procedures [21], with a detailed description provided in Appendix B. 165 
 8 
The total direct non-medical and indirect cost per participant was estimated for the 166 
duration of the hospital admission. This included costs incurred by the participant and 167 
their main family member/carer who stayed with them during their hospital admission. 168 
The total direct non-medical and indirect cost was estimated by adding the costs on the 169 
day of admission, to the average daily cost for each subsequent period between 170 
interviews multiplied by the duration of each subsequent period.  171 
 172 
The direct non-medical costs included the cost of transportation, food, drinks, toiletries, 173 
clothing and other items bought during the hospital admission. For indirect costs, we 174 
recorded whether participants or their carers had taken time off work, and if so, the 175 
amount of time, and multiplied this by their self-reported income [22]. For self-reported 176 
income, we asked participants their average weekly earnings from formal and informal 177 
employment, and divided by the average number of days worked per week to estimate 178 
average income per day worked. User fees are not charged for care in the hospital, but 179 
hospital inpatients may still incur costs of purchasing medications through private 180 
providers if there are issues with stocks at the hospital. Participants in this study did not 181 
report incurring any such costs.     182 
 183 
Health-related quality of life 184 
The Chichewa version of the EuroQoL EQ-5D-3L [23] was used to assess HRQoL of 185 
participants recruited into this study. Participants completed both the descriptive EQ-186 
5D-3L system and the accompanying visual analogue scale (VAS). We derived the EQ-187 
5D utility scores using the Zimbabwean EQ-5D tariff set [24], and report participants’ 188 
responses to the visual analogue scale (VAS). The Zimbabwean tariff set generates 189 
utility scores ranging between -0.145 and 1.0, with 1.0 corresponding to “perfect health” 190 
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and 0 representing a health state considered to be equivalent to death. The visual 191 
analogue scale is similar to a thermometer, and ranges from 100 (best imaginable health 192 
state) to 0 (worst imaginable health state). Appendix C provides a detailed description 193 
of procedures used.  194 
 195 
Statistical Analysis 196 
All analyses were undertaken in Stata version 13.1 (Stata Corporation, Texas, USA) 197 
and R version is 3.2.4 (R Foundation for Statistical Computing, Vienna, Austria). All 198 
costs were converted into 2014 US Dollars using market exchange rates and 199 
International Dollars using purchasing power parity conversion factors [25, 26]. 200 
Principal component analysis was used to generate wealth quintiles by combining 201 
socioeconomic variables, which included nine household assets, and home environment 202 
variables [27]. The discharge medical diagnosis was coded as the highest level of the 203 
four-level ICD-9-CM recorded by the study doctors. Where there were fewer than four 204 
participants with the same discharge medical diagnosis, the diagnosis was based upon 205 
the next highest level of the four-level ICD-9-CM code recorded by the study doctors.  206 
 207 
We estimated the total direct health provider cost, total direct non-medical and indirect 208 
cost and total societal cost according to each participant’s discharge medical diagnosis. 209 
The total societal cost per participant was estimated by summing the total direct health 210 
provider cost, and the total direct non-medical and indirect cost (the latter calculated by 211 
summing duration weighted cost estimates from each of the cost assessments). For each 212 
of these three cost categories we investigated differences, firstly by HIV status, and 213 
secondly by whether or not the participant was on ART at the time of admission. As 214 
the cost data was skewed, we used non-parametric bootstrap methods with 1000 215 
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bootstrap replications to derive 95% confidence intervals (CI) for mean cost differences 216 
for relevant cost categories [28]. In addition, we undertook multivariable analysis to 217 
investigate the independent effects of HIV and ART status on these costs. As all 218 
participants incurred a cost, and cost data was skewed, we used generalized linear 219 
models (GLM) for multivariable analyses of cost data [29]. We ran model diagnostics 220 
to determine the optimal choices for the distributional family and link function for these 221 
GLM models [30]. 222 
 223 
For HRQoL assessments, we estimated the EQ-5D utility and VAS scores on admission, 224 
on discharge and the change in scores. For the discharge EQ-5D utility score and VAS 225 
score, we used the last recorded assessment, and attributed a value of zero for those 226 
who died in hospital [31].  227 
  228 
We investigated differences in the admission EQ-5D utility and VAS scores by HIV 229 
status, and for those who were HIV-positive, by whether or not they were taking ART 230 
on admission. In addition, we constructed multivariable models to investigate the 231 
independent effects of HIV and ART status on HRQoL assessment on admission. EQ-232 
5D utility and VAS scores were non-normally distributed, skewed and truncated. 233 
Therefore, we used non-parametric bootstrap methods, with 1000 bootstrap replications, 234 
to derive 95% confidence intervals (CI) for mean differences. For the multivariable 235 
analysis, we evaluated four commonly used estimators to analyse these data: ordinary 236 
least squares (OLS) regression; Tobit regression, Fractional logit regression, and 237 
censored least absolute deviations (CLAD) regression [32-34]. We compared the mean 238 
squared error (MSE), mean absolute error (MAE) and the coefficient of determination 239 
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(r2) statistics between the observed and estimated scores for the whole sample, and for 240 
sub-groups of the sample to determine the choice of preferred estimator.  241 
 242 
For all multivariable analyses of cost and HRQoL outcomes we ran two alternative 243 
models, the first adjusted for HIV status, age and sex, and the second additionally 244 
adjusted for marital status, educational attainment, income, socio-economic position 245 
and the discharge medical diagnosis. We included the discharge medical diagnosis in 246 
these models as the aim was to investigate independent associations between HIV and 247 
ART status, and cost or HRQoL outcomes. 248 
 249 
Sensitivity Analysis 250 
We undertook sensitivity analyses to investigate the impact of using an alternative tariff 251 
set to determine EQ-5D utility scores. We used the UK York A1 tariff [35], which has 252 
been found to translate health states with ‘severe’ problems in one or more of the five 253 
dimensions to lower EQ-5D utility scores than the Zimbabwean tariff [24].   254 
 255 
 256 
Results 257 
During the study period 1,010 eligible participants were admitted to the QECH’s adult 258 
medical wards (Figure 1). In total, 87 (8.7%) died and 30 (3.0%) left hospital or were 259 
discharged before recruitment was possible. Of the remaining 893 eligible participants, 260 
805 (90.1%) consented to participate, and medical notes were found for 647 (80.4%).  261 
 262 
Table 1 shows the characteristics of participants by HIV status. Of the 647 participants 263 
recruited into the study and for whom the medical notes were found, 134 (20.7%) died 264 
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in hospital. Overall, 447 (69.1%) were HIV-positive, and 25 (3.9%) had an unknown 265 
HIV status. Of those who were HIV-positive, 339 (75.8%) were already on ART on 266 
admission. Appendix B details the health provider per diem cost for each of the three 267 
wards; unit costs per dosage of drug dispensed through the QECH’s pharmacy 268 
department; and unit costs for investigations and procedures performed.   269 
 270 
Table 2 shows the participant characteristics, HIV status and outcomes by the 35 271 
identified discharge medical diagnoses. The three most common reasons for hospital 272 
admission were: pneumonia (93/647; 14.4%); septicaemia (58/647; 9.0%); and 273 
pulmonary TB (54/647; 8.3%). The mean duration of hospital admission amongst all 274 
participants was 12.0 days (95%CI: 11.0-13.1). The mean duration of admission for 275 
participants who were HIV-negative, HIV-positive and not on ART, and HIV-positive 276 
on ART was 10.8 days (95%CI: 8.8-12.8), 15.0 days (95%CI: 12.0-18.0) and 12.2 days 277 
(95%CI: 10.8-13.7), respectively.  278 
 279 
The mean total health provider cost per individual hospital admission, and the mean 280 
average daily cost, were US$313.65 (INT$788.83) and US$32.14 (INT$80.77), 281 
respectively (Table 3). Ward costs accounted for 61.2%, investigations and medical 282 
procedures accounted for 35.5%, and drugs accounted for 3.6% of the total 283 
International Dollar costs. The three discharge medical diagnoses associated with the 284 
highest mean total health provider costs were: cryptococcal meningitis (US$846.24); 285 
retreatment for TB (US$741.14); and TB of the meninges and central nervous system 286 
(US$721.02) (Figure 2). 287 
 288 
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Table 4 shows the mean total direct non-medical and indirect costs, and the mean total 289 
societal costs, for all participants by discharge medical diagnosis. The mean total direct 290 
non-medical and indirect cost per hospital admission was US$87.84 (INT$243.99). The 291 
mean total societal cost per hospital admission was US$401.48 (INT$1032.82). The 292 
three discharge medical diagnoses associated with the highest mean total societal costs 293 
were: TB of the meninges and central nervous system (US$1228.38); cryptococcal 294 
meningitis (US$977.75); and retreatment for TB (US$915.32).  295 
 296 
The EQ-5D utility and VAS scores for all participants, and by discharge medical 297 
diagnosis, are shown in Table 5. For all participants, the mean EQ-5D utility score and 298 
VAS score on admission was 0.483 (SE: 0.01) and 52.8 (SE: 0.8), respectively (Table 299 
5). The three discharge medical diagnoses associated with the lowest EQ-5D utility 300 
scores on admission were TB of the meninges and central nervous system, candidiasis 301 
and cerebrovascular disease (Figure 3). For all participants, the mean change in EQ-5D 302 
utility and VAS scores was 0.020 (SE: 0.01) and 0.4 (SE: 1.2), respectively. The mean 303 
change in EQ-5D utility score, derived using the UK tariff set, was 0.116 (SE: 0.02) 304 
(Appendix E). 305 
 306 
Table 6 shows the costs for participants by their HIV status. The mean total provider 307 
cost of admission for participants who were HIV-negative, HIV-positive and not on 308 
ART, and HIV-positive on ART, was US$267.07, US$422.90 and US$316.03, 309 
respectively. The mean total provider cost of admission for HIV-positive participants 310 
was US$74.78 (bootstrap 95%CI: US$25.41-US$124.15) higher than for HIV-negative 311 
participants. Amongst HIV-positive participants, the mean total provider cost was 312 
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US$106.87 (bootstrap 95%CI: US$25.09-US$188.64) lower for those already on ART 313 
on admission.  314 
 315 
There were no significant differences in the mean total direct non-medical and indirect 316 
cost by HIV or ART status. The mean total societal cost of hospital admission for 317 
participants who were HIV-negative, HIV-positive and not on ART, and HIV-positive 318 
on ART, was US$342.20, US$546.61 and US$404.65, respectively. The mean total 319 
societal cost of admission for HIV-positive participants was US$96.76 (bootstrap 320 
95%CI: US$17.11-US$176.40) higher than for HIV-negative participants. Amongst 321 
HIV-positive participants, the mean total societal cost of admission was US$141.95 322 
(bootstrap 95%CI: US$24.73-US$259.17) lower for those already on ART on 323 
admission.  324 
 325 
The mean admission EQ-5D utility score for participants who were HIV-negative, HIV-326 
positive and not on ART, and HIV-positive on ART, was 0.532, 0.447 and 0.472, 327 
respectively (Table 6). The mean admission EQ-5D utility score amongst HIV-negative 328 
participants was 0.066 (bootstrap 95%CI: 0.019-0.114) higher than for HIV-positive 329 
participants. There were no significant differences in the admission EQ-5D utility 330 
scores between HIV-positive participants who were on or not on ART. 331 
 332 
In the multivariable analysis (Model 1; Table 7), after adjusting for participant 333 
characteristics and discharge medical diagnosis, the mean total provider costs of 334 
hospital admission was US$51.04 (95%CI: US$7.23-US$94.86) lower for those who 335 
were HIV-positive and on ART on admission compared to those who were HIV-336 
positive and not on ART.  There was no significant difference in the mean total provider 337 
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costs between HIV-negative individuals and HIV-positive individuals not on ART on 338 
admission. After adjusting for discharge medical diagnosis (Model 2), we did not find 339 
any significant differences in either mean total direct non-medical and indirect costs or 340 
mean total societal costs by HIV or ART status.  341 
 342 
The findings of the multivariable analysis exploring the relationship between HIV 343 
status and the EQ-5D utility scores on admission are shown in Table 8. In the 344 
multivariable analysis, the model diagnostics showed that the OLS estimator performed 345 
as well or better than the other estimators (Appendix F). In the multivariable analysis, 346 
after adjusting for individual characteristics and the discharge medical diagnosis, the 347 
mean admission EQ-5D utility score amongst those who were HIV-negative was 0.131 348 
(95%CI: 0.064-0.198) higher than amongst those who were HIV-positive and not on 349 
ART on admission. There were no significant differences in the adjusted EQ-5D utility 350 
scores between those who were HIV-positive and either taking or not taking ART on 351 
admission. 352 
 353 
 354 
 355 
 356 
 357 
 358 
 359 
 360 
 361 
Discussion 362 
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The main findings of this study are the high costs incurred in managing adults admitted 363 
to hospital in a resource-poor setting with high HIV prevalence. Health provider costs 364 
were especially high for managing HIV-associated illnesses. However, costs were 365 
substantially lower, with significantly shorter duration of admission and less risk of 366 
death, if individuals were already receiving ART on hospital admission. Health-related 367 
quality of life was especially poor amongst those admitted for HIV-associated illnesses, 368 
and overall, was significantly lower in HIV-positive than HIV-negative participants. 369 
Our data also highlights the substantial burden imposed on the finances of patients and 370 
their families as a result of hospitalisation. Even though patients do not pay for medical 371 
services, the mean cost from the patient perspective was US$87.84, amounting to 372 
catastrophic costs for most patients.  373 
 374 
In this study, the average health provider cost of managing individuals in hospital was 375 
US$313.65, with substantially higher costs for HIV-positive individuals and for AIDS-376 
defining diseases. Total provider costs of one year of ART have been estimated to be 377 
US$136 (in 2011 prices) in Malawi [36]. HIV-positive individuals will continue to be 378 
at increased risk of hospitalisation after initiation of ART, especially if treatment is 379 
started late, but at a population level, timely ART initiation will reduce the absolute 380 
numbers requiring admission [37]. Moreover, the substantial cost differences found 381 
between those taking and not taking ART in this study raise the prospect of 382 
considerably higher savings from ART than would be anticipated on the basis of 383 
admission rates alone. This difference remained even after accounting for differences 384 
in cause of admission. Thus, the costs incurred in providing early initiation of ART to 385 
greater numbers of people living with HIV may be offset by larger cost savings than 386 
have been appreciated. Importantly, we found that the majority of patients were aware 387 
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of their HIV status, and many of those who were HIV-positive had already started ART. 388 
In the study we were unable to ascertain the stage of participants’ HIV infection, or 389 
when ART was initiated.  390 
 391 
In Malawi, hospital care is provided free but users inevitably incur some costs in 392 
accessing care, including for transportation to and from hospital, and losses in income. 393 
The mean direct non-medical and indirect cost was estimated at US$86.93. The 394 
majority of Malawians live on less than $2 a day [38], highlighting the catastrophic 395 
impact of a hospitalisation on the finances of Malawians. Whilst preventing illness will 396 
have a major impact on reducing this burden, offering social security benefits to those 397 
affected needs to be explored further [39]. 398 
 399 
Tuberculosis continues to be one of the most common reasons for medical inpatient 400 
care in sub-Saharan Africa [1]. As in previous studies and surveillance data, the 401 
majority of TB patients in our study were HIV positive. Individuals with HIV and TB 402 
coinfection reported very poor HRQoL, with hospitalisation resulting in substantial 403 
costs for them and for the health system. Hospitalisation may be unavoidable for some 404 
TB patients, considering the severity of their illness, but moving the later stages of care 405 
to community-based TB services, which are already established in much of the region, 406 
could reduce these costs [40]. Rapid scale up TB preventive therapy and systematic TB 407 
screening on all health encounters are urgently required [41]. 408 
  409 
The World Health Organization’s (WHO) prequalification of medicines programme 410 
ensures high quality drugs enter African healthcare markets at reasonable prices [42]. 411 
In our study, we found drugs accounted for a lower proportion of total health provider 412 
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costs than investigations and procedures. The WHO prequalification programme does 413 
extend to diagnostics and medical devices; however, the focus has predominantly been 414 
around rapid diagnostic and point of care tests. Extending these services to all medical 415 
consumables and equipment may reduce costs, and facilitate decentralisation of 416 
diagnostic services to district level hospitals.   417 
 418 
We used the EuroQol EQ-5D measure to provide two assessments of HRQoL, 419 
including one (EQ-5D utility score) that can be used to inform cost-utility analyses. The 420 
mean EQ-5D utility score reported was 0.498, with HIV-positive inpatients reporting 421 
much lower HRQoL than HIV-negative inpatients. The mean EQ-5D utility score 422 
amongst HIV-positive inpatients who had not started ART (0.447) was considerably 423 
lower than reported by HIV-positive outpatients in the catchment population of this 424 
hospital (0.8) [21]. This further reinforces the value of early diagnosis and ART 425 
initiation to prevent serious and debilitating illness, and maintenance of HRQoL. Of 426 
concern were the minimal changes in HRQoL outcomes during admission, although 427 
this has to be interpreted in the context of high inpatient mortality. Health utility data 428 
are notably lacking in this region, constraining the use of cost-utility analyses in 429 
economic evaluations [43, 44]. This study provides an extensive catalogue of health 430 
utility scores, including those derived using an alternative tariff set (UK York A1), to 431 
inform cost-utility analyses for a range of interventions, not just limited to HIV.   432 
 433 
Study limitations include the relatively small number of participants recruited for a few 434 
of the medical conditions; discharge medical diagnoses based on the assessment of one 435 
medical doctor; and the fact the study was undertaken in a large central teaching 436 
hospital that limits generalisability to smaller district hospital settings.  In addition, we 437 
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were unable to examine economic outcomes in the sickest group of patients, those who 438 
died before recruitment was possible, or whose medical notes were not found. However, 439 
this is the first study we are aware of that estimates economic costs and HRQoL 440 
outcomes amongst a cohort of adults admitted to hospital for medical reasons in an 441 
African context with high HIV prevalence. We collected individual-level data on 442 
healthcare resources used, direct non-medical and indirect costs incurred, and examined 443 
HRQoL outcomes. We undertook a primary costing study to estimate the costs of all 444 
healthcare resources used, and provide estimates of the total health provider costs.  445 
 446 
Our findings highlight the catastrophic costs and poor HRQoL outcomes associated 447 
with hospitalisation in a sub-Saharan cohort with high HIV prevalence. Importantly, as 448 
countries in sub-Saharan Africa move towards immediate initiation of ART treatment 449 
for people living with HIV, policy makers will need to be aware of the potential for 450 
substantial cost savings from averting serious HIV-associated illnesses and through 451 
earlier case detection of tuberculosis.   452 
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Figure 1: Recruitment of participants 667 
 668 
Readmissions were coded as a separate admission 669 
 670 
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Figure 2: Mean total costs by discharge medical diagnosis 672 
 673 
*Except in Labour 674 
**Except that caused by TB or Cryptococcal 675 
Total societal cost equates to the total direct health provider cost plus the total direct non-medical and indirect cost 676 
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Figure 3: Frequency, distribution and density of EQ-5D utility scores by medical 685 
diagnosis 686 
 687 
*Except in Labour 688 
**Except that caused by TB or Cryptococcal 689 
  690 
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Table 1: Participant characteristics (n=647)   691 
  HIV 
negative 
HIV 
positive 
HIV status 
unknown 
  n (%) n (%) n (%) 
All  175 447 25 
Sex Male 93 (53.1%) 230 (51.5%) 20 (80.0%) 
Female 82 (46.9%) 217 (48.5%) 5 (20.0%) 
Age group 
(years) 
18-24 31 (17.7%) 38 (8.5%) 5 (20.0%) 
25-34 36 (20.6%) 143 (32.0%) 3 (12.0%) 
35-44 23 (13.1%) 156 (34.9%) 8 (32.0%) 
45+ 84 (48.0%) 105 (23.5%) 9 (36.0%) 
Missing 1 (0.6%) 5 (1.1%) 0 (0%) 
Marital 
status 
Single (never-married) 28 (16.0%) 38 (8.5%) 5 (20.0%) 
Married/cohabiting 101 (57.7%) 243 (54.4%) 10 (10.0%) 
Separated/divorced 12 (6.9%) 85 (19.0%) 2 (8.0%) 
Widower/widow 29 (16.6%) 59 (13.2%) 3 (12.0%) 
Missing 5 (2.9%) 22 (4.9%) 5 (20.0%) 
Educational 
attainment* 
Up to standard 8 117 (66.9%) 233 (52.1%) 11 (44.0%) 
Up to form 6 46 (26.3%) 182 (40.7%) 8 (32.0%) 
University or training college 7 (4.0%) 10 (2.2%) 1 (4.0%) 
Missing 5 (2.9%) 22 (4.9%) 5 (20.0%) 
Income** Not working 94 (53.7%) 183 (40.9%) 17 (68.0%) 
Up to 4,000 kwacha/week 21 (12.0%) 62 (13.9%) 3 (12.0%) 
4,000 to 8,000 kwacha/week 18 (10.3%) 59 (13.2%) 2 (8.0%) 
8,000 to 12,000 kwacha/week 7 (4.0%) 32 (7.2%) 0 (0%) 
Over 12,000 kwacha/week 33 (18.9%) 104 (23.3%) 3 (12.0%) 
Missing 2 (1.1%) 7 (1.6%) 0 (0%) 
Employment 
status 
Formal employment 31 (17.7%) 93 (20.8%) 4 (16.0%) 
Informal employment/Unemployed 50 (28.6%) 161 (36.0%) 10 (40.0%) 
School/University 14 (8.0%) 11 (2.5%) 4 (16.0%) 
Retired 1 (0.6%) 3 (0.7%) 0 (0%) 
Housework 68 (38.9%) 130 (29.1%) 7 (28.0%) 
Sick leave 9 (5.1%) 43 (9.6%) 0 (0%) 
Missing 2 (1.1%) 6 (1.3%) 0 (0%) 
Socio-
economic 
position*** 
Highest quintile 34 (19.4%) 90 (20.1%) 3 (12.0%) 
2nd highest quintile 23 (13.1%) 92 (20.6%) 4 (16.0%) 
Middle quintile 31 (17.7%) 90 (20.1%) 4 (16.0%) 
2nd lowest quintile 34 (19.4%) 82 (18.3%) 3 (12.0%) 
Lowest quintile 45 (25.7%) 67 (15.0%) 6 (24.0%) 
Missing 8 (4.6%) 26 (5.8%) 5 (20.0%) 
ART status Not on ART   108 (24.2%)  
On ART  339 (75.8%)  
Outcome Discharged home alive  151 (86.3%) 342 (76.5%) 20 (80.0%) 
Died as inpatient 24 (13.7%) 105 (23.5%) 5 (20.0%) 
ART: Anti-retroviral treatment 692 
*Up to Standard 8 equivalent to completing Primary school; Up to form 6 equivalent to completing Secondary/High school.  693 
**426 Malawian Kwacha=US$1 in 2014 694 
***Socio-economic position estimated though undertaking principal component analysis of responses to asset ownership and 695 
housing environment amongst respondents 696 
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Table 2: Characteristics of participants by the discharge medical diagnosis (n=647) 698 
 
Discharge medical diagnosis 
 
n 
Sex Age HIV status Outcome Days of admission 
Male (n/%) 45+ (n/%) HIV positive (n/%) On ART (n/%) Died (n/%) Mean (SE) 
Pulmonary Tuberculosis 54 39 (72.2%) 10 (18.5%) 47 (87.0%) 34 (63.0%) 14 (25.9%) 23.9 (3.0) 
Tuberculosis of the meninges and central nervous system 16 10 (62.5%) 5 (31.3%) 16 (100%) 11 (68.8%) 8 (50.0%) 38.3 (7.3) 
Tuberculosis of intestines, peritoneum 9 6 (66.7%) 3 (33.3%) 7 (77.8%) 4 (44.4%) 3 (33.3%) 19.2 (5.6) 
Tuberculosis of bones and joint 4 3 (75.0%) 3 (75.0%) 2 (50.0%) 2 (50.0%) 2 (50.0%) 19.0 (5.6) 
Tuberculosis of other organs 15 10 (66.7%) 5 (33.3%) 12 (80.0%) 9 (60.0%) 7 (46.7%) 26.2 (8.6) 
Miliary Tuberculosis 17 11 (64.7%) 4 (23.5%) 14 (82.4%) 12 (70.6%) 10 (58.8%) 10.7 (1.0) 
Tuberculosis - retreatment 6 4 (66.7%) 1 (16.7%) 5 (83.3%) 5 (83.3%) 2 (33.3%) 41.2 (11.8) 
Septicaemia* 58 24 (41.4%) 13 (22.4%) 37 (63.8%) 30 (51.7%) 10 (17.2%) 8.4 (1.0) 
Candidiasis 6 2 (33.3%) 1 (16.7%) 6 (100%) 5 (83.3%) 1 (16.7%) 5.7 (1.7) 
Cryptococcal meningitis 36 27 (75.0%) 3 (8.3%) 36 (100%) 27 (75.0%) 9 (25.0%) 15.9 (1.8) 
Viral infection 8 4 (50.0%) 1 (12.5%) 8 (100%) 6 (75.0%) 4 (50.0%) 15.3 (3.9) 
Pneumocystis Jivorecii pneumonia 9 4 (44.4%) 1 (11.1%) 9 (100%) 3 (33.3%) 2 (22.2%) 13.4 (1.9) 
Malaria 13 3 (23.1%) 3 (23.1%) 10 (76.9%) 6 (46.2%) 1 (7.7%) 5.2 (1.6) 
Kaposi’s sarcoma 20 16 (80.0%) 2 (10.0%) 20 (100%) 17 (85.0%) 5 (25.0%) 9.1 (1.2) 
Neoplasms - excluding Kaposi's 7 4 (57.1%) 3 (42.9%) 3 (42.9%) 2 (28.6%) 1 (14.3%) 15.6 (2.1) 
Diabetes mellitus without complications 5 0 (0.0%) 3 (60.0%) 0 (0%) 0 (0%) 0 (0%) 3.8 (1.2) 
Diabetes mellitus with complications 9 5 (55.6%) 6 (66.7%) 1 (11.1%) 1 (11.1%) 0 (0%) 8.2 (1.2) 
Anaemia 35 14 (40.0%) 11 (31.4%) 26 (74.3%) 24 (68.6%) 6 (17.1%) 9.4 (1.3) 
Mental health disorders 9 6 (66.7%) 2 (22.2%) 2 (22.2%) 1 (11.1%) 0 (0%) 6.6 (1.9) 
Meningitis** 37 11 (29.7%) 11 (29.7%) 26 (70.3%) 19 (51.4%) 5 (13.5%) 9.2 (0.8) 
Epilepsy; Convulsions 10 5 (50.0%) 2 (20.0%) 3 (30.0%) 3 (30.0%) 1 (10.0%) 6.3 (0.9) 
Other neurological problems 16 12 (75.0%) 4 (25.0%) 8 (50.0%) 8 (50.0%) 1 (6.3%) 10.3 (2.6) 
Cerebrovascular disease 25 12 (48.0%) 16 (64.0%) 10 (40.0%) 6 (24.0%) 2 (8.0%) 8.6 (1.1) 
Hypertension 7 5 (71.4%) 5 (71.4%) 2 (28.6%) 1 (14.3%) 2 (28.6%) 11.1 (4.4) 
Congestive heart failure; non-hypertensive 15 6 (40.0%) 12 (80.0%) 2 (13.3%) 0 (0.0%) 5 (33.3%) 9.4 (2.1) 
Other cardiovascular problems 12 4 (33.3%) 8 (66.7%) 5 (41.7%) 4 (33.3%) 2 (16.7%) 10.2 (3.7) 
Pneumonia** 93 51 (54.8%) 23 (24.7%) 74 (79.6%) 56 (60.2%) 13 (14.0%) 7.5 (0.9) 
Other respiratory problems 11 3 (27.3%) 6 (54.6%) 5 (45.5%) 4 (36.4%) 1 (9.1%) 9.9 (2.4) 
Acute - Intestinal infection 10 10 (100%) 4 (40.0%) 6 (60.0%) 5 (50.0%) 1 (10.0%) 12.6 (3.5) 
Chronic - Intestinal infection 14 5 (35.7%) 4 (28.6%) 11 (78.6%) 10 (71.4%) 4 (28.6%) 6.7 (1.4) 
Upper gastrointestinal disorders 11 2 (18.2%) 4 (36.4%) 8 (72.7%) 7 (63.6%) 2 (18.2%) 5.7 (0.6) 
Liver disease 14 8 (57.1%) 4 (28.6%) 9 (64.3%) 6 (42.9%) 6 (42.9%) 10.0 (1.9) 
Diseases of the genitourinary system 18 7 (38.9%) 8 (44.4%) 14 (77.8%) 9 (50.0%) 3 (16.7%) 7.7 (1.3) 
Diseases of the musculoskeletal system 6 5 (83.3%) 4 (66.7%) 2 (33.3%) 1 (16.7%) 0 (0%) 15.0 (4.2) 
Other problems (<5 cases) 12 5 (41.7%) 3 (25.0%) 1 (8.3%) 1 (8.3%) 1 (8.3%) 7.3 (0.9) 
*Except in Labour 699 
**Except that caused by TB or Cryptococcal 700 
 701 
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 Table 3: Total direct health provider costs by discharge medical diagnosis (n=647) 702 
Discharge medical diagnosis 
 Total health provider cost Average daily cost Mean proportion of total heath provider cost 
2014 US Dollars 2014 INT Dollars 2014 US Dollars 2014 INT Dollars % Drugs % Investigations & 
Procedures 
% Ward 
stay N Mean (SE) Mean (SE) Mean (SE) Mean (SE) 
All 647 313.65 (12.2) 788.83 (27.7) 32.14 (0.9) 80.77 (1.9) 3.6 35.5 61.2 
Pulmonary tuberculosis 54 477.57 (51.5) 1252.59 (137.2) 23.67 (1.0) 61.11 (2.6) 3.4 26.2 70.8 
Tuberculosis of the meninges and central nervous system 16 721.02 (117.3) 1891.95 (306.6) 32.93 (5.7) 87.60 (15.5) 2.9 33.0 64.6 
Tuberculosis of intestines, peritoneum 9 429.92 (97.2) 1119.28 (252.3) 26.24 (3.6) 68.23 (9.3) 3.1 29.3 67.9 
Tuberculosis of bones and joint 4 376.51 (106.7) 1016.96 (288.9) 19.82 (0.9) 53.62 (2.03) 1.7 19.8 78.9 
Tuberculosis of other organs 15 523.78 (138.1) 1386.15 (378.5) 25.95 (2.5) 66.52 (6.0) 3.6 29.1 67.6 
Miliary tuberculosis 17 289.61 (25.5) 753.68 (66.9) 28.16 (1.9) 73.22 (4.8) 3.1 35.8 61.5 
Tuberculosis - retreatment 6 741.14 (203.4) 1943.75 (535.0) 20.24 (2.1) 52.69 (5.4) 3.6 15.4 81.7 
Septicaemia* 58 222.13 (18.0) 580.97 (47.3) 33.71 (2.3) 87.84 (6.0) 2.4 40.4 57.5 
Candidiasis 6 153.08 (43.1) 395.98 (113.9) 31.12 (6.0) 77.70 (11.9) 2.8 35.5 62.2 
Cryptococcal meningitis 36 846.24 (101.9) 1583.26 (138.6) 64.26 (9.5) 114.49 (10.9) 20.9 32.6 46.8 
Viral infection 8 300.80 (70.1) 808.37 (192.2) 25.34 (5.7) 66.71 (14.6) 1.8 21.4 77.4 
Pneumocystis Jivorecii pneumonia 9 325.56 (28.3) 849.35 (75.5) 26.79 (3.0) 69.55 (7.6) 2.9 29.9 67.3 
Malaria 13 179.01 (36.0) 439.87 (94.3) 44.78 (6.7) 106.46 (14.4) 7.2 44.2 48.8 
Kaposi’s sarcoma 20 230.99 (25.8) 609.69 (69.4) 28.99 (2.7) 75.55 (6.7) 2.5 35.5 62.5 
Neoplasms - excluding Kaposi's 7 320.31 (36.8) 839.86 (99.2) 21.08 (0.8) 54.88 (1.5) 2.6 19.1 78.4 
Diabetes mellitus without complications 5 158.72 (40.3) 403.59 (106.2) 46.07 (8.6) 116.25 (20.7) 5.5 50.7 43.8 
Diabetes mellitus with complications 9 217.13 (31.1) 574.67 (82.3) 30.54 (4.6) 80.10 (11.4) 3.1 36.7 60.2 
Anaemia 35 251.79 (25.8) 678.01 (70.9) 33.43 (4.1) 89.61 (11.5) 1.7 39.7 58.9 
Mental health disorders 9 186.64 (38.4) 496.94 (103.3) 33.14 (4.2) 87.91 (10.8) 2.0 44.5 53.5 
Meningitis** 37 250.76 (17.8) 646.86 (45.9) 30.76 (1.8) 79.23 (4.6) 3.2 37.2 59.9 
Epilepsy; Convulsions 10 195.01 (17.1) 501.68 (44.4) 34.84 (3.9) 88.86 (8.9) 2.6 44.5 53.0 
Other neurological problems 16 261.58 (48.6) 682.28 (127.9) 32.85 (3.3) 86.00 (8.5) 1.5 42.1 56.6 
Cerebrovascular disease 25 207.26 (25.2) 551.48 (64.5) 26.66 (1.6) 71.18 (4.2) 1.9 32.5 65.8 
Hypertension 7 234.21 (79.1) 633.97 (212.2) 25.47 (3.6) 68.18 (8.6) 1.7 31.6 66.8 
Congestive heart failure; non-hypertensive 15 239.51 (47.6) 646.48 (132.4) 27.82 (2.7) 74.61 (7.3) 1.4 33.4 65.2 
Other cardiovascular problems 12 269.03 (81.0) 702.02 (205.2) 29.99 (2.3) 79.42 (6.0) 2.7 38.4 59.1 
Pneumonia** 93 198.77 (14.4) 517.30 (39.4) 30.81 (0.9) 79.04 (2.2) 2.2 39.7 58.4 
Other respiratory problems 11 242.98 (56.0) 641.18 (148.1) 25.93 (2.2) 68.01 (5.3) 2.6 29.5 68.1 
Acute - Intestinal infection 10 250.82 (53.1) 667.67 (147.6) 23.10 (1.8) 60.53 (4.6) 3.3 23.7 73.5 
Chronic - Intestinal infection 14 249.26 (61.0) 658.73 (166.3) 50.21 (18.8) 133.16 (52.0) 2.7 43.5 54.3 
Upper gastrointestinal disorders 11 193.04 (46.0) 508.40 (129.3) 32.93 (5.0) 86.30 (14.1) 2.2 39.2 59.0 
Liver disease 14 345.84 (103.9) 940.74 (287.6) 31.82 (3.2) 85.74 (8.8) 1.4 42.7 56.1 
Diseases of the genitourinary system 18 202.25 (24.5) 537.57 (67.0) 29.02 (1.7) 76.68 (4.2) 2.1 38.1 60.1 
Diseases of the musculoskeletal system 6 332.33 (79.2) 875.32 (203.1) 23.59 (1.4) 62.42 (3.9) 1.9 28.1 70.1 
Other problems (<5 cases) 12 179.93 (23.3) 477.10 (58.2) 25.13 (1.5) 66.92 (3.6) 1.9 30.6 67.6 
*Except in Labour 703 
**Except that caused by TB or Cryptococcal 704 
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Table 4: Total direct non-medical and indirect, and societal costs by discharge medical diagnosis (n=647) 706 
Discharge medical diagnosis 
 Total direct non-medical and indirect cost Total societal cost 
2014 US Dollars 2014 INT Dollars 2014 US Dollars 2014 INT Dollars 
N Mean (SE) Mean (SE) Mean (SE) Mean (SE) 
All 647 87.84 (10.2) 243.99 (28.3) 401.48 (18.8) 1032.82 (48.1) 
Pulmonary tuberculosis 54 135.59 (29.7) 376.64 (82.5) 613.16 (68.6) 1629.23 (185.1) 
Tuberculosis of the meninges and central nervous system 16 507.36 (205.6) 1409.33 (571.0) 1228.38 (284.7) 3301.29 (771.2) 
Tuberculosis of intestines, peritoneum 9 424.13 (336.4) 1178.14 (934.4) 854.05 (431.0) 2297.42 (1179.0) 
Tuberculosis of bones and joint 4 90.43 (34.9) 251.20 (97.1) 466.94 (134.3) 1268.16 (365.8) 
Tuberculosis of other organs 15 299.43 (189.7) 831.74 (526.9) 823.21 (318.7) 2217.89 (882.0) 
Miliary tuberculosis 17 48.55 (12.6) 134.86 (34.9) 338.16 (30.3) 888.54 (80.2) 
Tuberculosis - retreatment 6 174.18 (130.8) 483.83 (363.4) 915.32 (280.4) 2427.58 (744.8) 
Septicaemia* 58 38.05 (8.2) 105.68 (22.9) 260.17 (24.2) 686.65 (64.6) 
Candidiasis 6 25.86 (20.0) 71.84 (55.6) 178.94 (58.8) 467.81 (156.7) 
Cryptococcal meningitis 36 131.50 (44.1) 365.28 (122.4) 977.75 (113.6) 1948.54 (206.2) 
Viral infection 8 61.51 (32.9) 170.87 (91.4) 362.32 (89.5) 979.24 (245.7) 
Pneumocystis Jivorecii pneumonia 9 69.59 (28.2) 193.30 (78.2) 395.15 (50.6) 1042.65 (139.6) 
Malaria 13 124.91 (116.9) 346.97 (324.7) 303.92 (119.3) 786.85 (328.1) 
Kaposi’s sarcoma 20 81.66 (21.5) 226.84 (59.6) 312.65 (43.2) 836.53 (118.3) 
Neoplasms - excluding Kaposi's 7 49.03 (15.6) 136.19 (43.3) 369.34 (45.8) 976.06 (126.0) 
Diabetes mellitus without complications 5 21.63 (10.6) 60.07 (29.6) 180.34 (48.8) 463.66 (129.9) 
Diabetes mellitus with complications 9 220.34 (145.4) 612.05 (404.0) 437.47 (157.4) 1186.72 (435.9) 
Anaemia 35 57.20 (10.5) 158.90 (29.2) 308.99 (33.0) 836.91 (90.9) 
Mental health disorders 9 72.97 (30.3) 202.69 (84.1) 259.61 (53.0) 699.64 (142.8) 
Meningitis** 37 49.54 (10.3) 137.61 (28.7) 300.30 (23.1) 784.47 (61.4) 
Epilepsy; Convulsions 10 30.86 (19.8) 85.71 (55.0) 225.86 (27.9) 587.39 (75.7) 
Other neurological problems 16 31.98 (9.3) 88.84 (25.9) 293.56 (56.1) 771.12 (149.1) 
Cerebrovascular disease 25 42.98 (13.6) 119.39 (37.7) 250.24 (34.4) 670.87 (89.6) 
Hypertension 7 46.52 (24.1) 129.23 (66.9) 280.73 (102.3) 763.20 (276.4) 
Congestive heart failure; non-hypertensive 15 28.02 (7.3) 77.83 (20.2) 267.53 (49.3) 724.31 (136.6) 
Other cardiovascular problems 12 44.31 (16.6) 123.08 (46.0) 313.34 (93.1) 825.10 (239.4) 
Pneumonia** 93 33.36 (5.6) 92.65 (15.6) 232.12 (19.0) 609.95 (52.4) 
Other respiratory problems 11 46.70 (18.5) 129.71 (51.4) 289.67 (59.7) 770.89 (158.8) 
Acute - Intestinal infection 10 155.70 (53.4) 432.49 (148.3) 406.52 (94.4) 1100.17 (262.8) 
Chronic - Intestinal infection 14 26.29 (9.6) 73.03 (26.7) 275.55 (64.2) 731.76 (175.5) 
Upper gastrointestinal disorders 11 68.22 (41.2) 189.49 (114.5) 261.26 (58.0) 697.89 (162.8) 
Liver disease 14 56.37 (24.4) 156.57 (67.7) 402.21 (104.1) 1097.31 (288.1) 
Diseases of the genitourinary system 18 39.71 (13.3) 110.31 (37.0) 241.96 (30.3) 647.87 (82.4) 
Diseases of the musculoskeletal system 6 158.44 (93.6) 440.11 (260.1) 490.77 (111.2) 1315.43 (301.6) 
Other problems (<5 cases) 12 44.46 (16.4) 123.50 (45.6) 224.39 (34.0) 600.60 (86.8) 
*Except in Labour 707 
**Except that caused by TB or Cryptococcal 708 
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Table 5: Health-related quality of life outcomes by discharge medical diagnosis (n=640) 710 
 
Discharge medical diagnosis 
 
 
N 
EQ-5D utility scores (Zimbabwean tariff) VAS scores 
On admission Last recorded Change On admission Last recorded Change 
Mean (SE) Mean (SE) Mean (SE) Mean (SE) Mean (SE) Mean (SE) 
All 640 0.483 (0.01) 0.503 (0.01) +0.020 (0.01) 52.8 (0.8) 53.2 (1.3) +0.4 (1.2) 
Pulmonary tuberculosis 54 0.445 (0.04) 0.486 (0.05) +0.041 (0.04) 55.1 (3.0) 55.4 (5.0) +0.2 (4.4) 
Tuberculosis of the meninges and central nervous system 16 0.275 (0.08) 0.304 (0.09) +0.030 (0.12) 41.3 (7.2) 37.4 (10.1) -3.9 (8.6) 
Tuberculosis of intestines, peritoneum 9 0.524 (0.11) 0.430 (0.11) -0.094 (0.07) 50.0 (7.5) 42.2 (12.1) -7.8 (11.4) 
Tuberculosis of bones and joint 4 0.379 (0.12) 0.277 (0.16) -0.101 (0.10) 65.0 (9.6) 45.0 (26.3) -20.0 (17.3) 
Tuberculosis of other organs 15 0.542 (0.08) 0.376 (0.10) -0.166 (0.10) 51.0 (6.1) 41.3 (10.7) -9.7 (10.5) 
Miliary tuberculosis 17 0.393 (0.07) 0.185 (0.07) -0.208 (0.07) 38.5 (4.4) 20.9 (7.5) -17.6 (8.2) 
Tuberculosis - retreatment 6 0.577 (0.15) 0.545 (0.17) -0.032 (0.08) 73.3 (7.6) 54.2 (17.6) -19.2 (19.0) 
Septicaemia* 58 0.512 (0.04) 0.577 (0.04) +0.064 (0.04) 53.0 (2.9) 55.2 (4.2) +2.1 (3.8) 
Candidiasis 6 0.349 (0.09) 0.424 (0.10) +0.074 (0.08) 48.3 (11.7) 50.0 (11.8) +1.7 (1.7) 
Cryptococcal meningitis 36 0.478 (0.04) 0.474 (0.06) -0.004 (0.06) 56.4 (3.3) 52.2 (5.6) -4.1 (6.1) 
Viral infection 8 0.589 (0.10) 0.395 (0.15) -0.195 (0.12) 56.3 (9.8) 41.9 (15.9) -14.4 (12.2) 
Pneumocystis Jivorecii pneumonia 8 0.559 (0.08) 0.501 (0.15) -0.058 (0.16) 55.0 (8.0) 58.8 (13.3) +3.8 (11.0) 
Malaria 13 0.521 (0.07) 0.514 (0.08) -0.006 (0.03) 53.2 (6.6) 53.9 (6.5) +0.8 (11.0) 
Kaposi’s sarcoma 20 0.415 (0.06) 0.402 (0.06) -0.014 (0.05) 48.3 (3.5) 46.5 (7.2) +0.8 (1.4) 
Neoplasms - excluding Kaposi's 7 0.567 (0.08) 0.342 (0.15) -0.225 (0.13) 52.9 (5.2) 42.1 (11.0) -10.7 (12.8) 
Diabetes mellitus without complications 5 0.682 (0.06) 0.815 (0.05) +0.133 (0.08) 73.4 (8.1) 80.4 (9.0) +7.0 (3.7) 
Diabetes mellitus with complications 9 0.405 (0.09) 0.443 (0.09) +0.038 (0.07) 54.4 (3.4) 57.2 (5.7) +2.8 (3.6) 
Anaemia 35 0.558 (0.04) 0.586 (0.06) +0.028 (0.05) 52.5 (3.2) 59.4 (5.4) +7.0 (5.3) 
Mental health disorders 9 0.629 (0.08) 0.705 (0.07) +0.076 (0.09) 61.1 (4.8) 67.2 (6.1) +6.1 (4.2) 
Meningitis** 36 0.484 (0.04) 0.611 (0.05) +0.126 (0.05) 49.9 (3.5) 59.3 (4.8) +9.4 (3.8) 
Epilepsy; Convulsions 10 0.561 (0.12) 0.560 (0.14) -0.002 (0.05) 57.0 (6.3) 64.0 (8.7) +7.0 (5.0) 
Other neurological problems 15 0.506 (0.06) 0.524 (0.07) +0.018 (0.06) 55.3 (4.1) 57.5 (6.8) +2.2 (5.7) 
Cerebrovascular disease 23 0.359 (0.05) 0.438 (0.07) +0.078 (0.04) 50.7 (4.9) 54.3 (5.3) +3.7 (5.5) 
Hypertension 7 0.387 (0.13) 0.419 (0.14) +0.032 (0.11) 58.6 (2.6) 50.7 (13.8) -7.9 (15.9) 
Congestive heart failure; non-hypertensive 15 0.569 (0.06) 0.476 (0.10) -0.092 (0.09) 57.0 (4.8) 49.7 (10.1) -7.3 (10.6) 
Other cardiovascular problems 12 0.500 (0.08) 0.613 (0.09) +0.113 (0.11) 55.0 (4.8) 59.2 (9.2) +4.2 (7.9) 
Pneumonia** 91 0.501 (0.03) 0.553 (0.03) +0.053 (0.03) 53.3 (2.4) 56.4 (3.4) +3.2 (2.8) 
Other respiratory problems 11 0.486 (0.08) 0.681 (0.09) +0.195 (0.09) 50.5 (5.7) 58.6 (7.5) +8.2 (8.3) 
Acute - Intestinal infection 10 0.487 (0.10) 0.516 (0.09) +0.029 (0.10) 56.0 (7.3) 48.0 (6.3) -8.0 (11.2) 
Chronic - Intestinal infection 14 0.434 (0.08) 0.400 (0.09) -0.035 (0.10) 50.0 (2.5) 42.9 (8.4) -7.1 (8.2) 
Upper gastrointestinal disorders 11 0.501  (0.06) 0.485 (0.10) -0.015 (0.10) 52.5 (3.7) 57.4 (9.9) +4.9 (10.5) 
Liver disease 14 0.436 (0.09) 0.405 (0.10) -0.032 (0.07) 45.0 (5.9 41.4 (10.3) -3.6 (8.4) 
Diseases of the genitourinary system 18 0.538 (0.06) 0.584 (0.09) +0.047 (0.08) 53.3 (4.9 59.7 (7.5) +6.4 (7.1) 
Diseases of the musculoskeletal system 6 0.416 (0.09) 0.338 (0.11) -0.078 (0.12) 47.5 (4.4) 61.7 (6.0) +14.2 (7.8) 
Other problems (<5 cases) 12 0.431 (0.07) 0.542 (0.08) +0.112 (0.09) 52.5 (3.9) 57.9 (7.2) +5.4 (7.5) 
*Except in Labour 711 
**Except that caused by TB or Cryptococcal 712 
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Table 6: Costs and health-related quality of life outcomes by HIV status  714 
    Mean differences 
(95% CI)** 
  N Mean (SE) HIV-positive v 
HIV-negative 
On ART v 
Not on ART 
Total health 
provider cost 
(2014 US$) 
HIV-negative 175 267.07 (20.2) 
74.78 
(25.41, 124.15) 
-106.87 
(-188.64, -25.09) 
HIV-positive: not on ART 108 422.90 (40.4) 
HIV-positive: on ART 339 316.03 (15.7) 
HIV status unknown 25 135.42 (19.7) 
Total direct non-
medical and 
indirect cost 
(2014 US$) 
HIV-negative 175 75.12 (18.7) 
21.98 
(-21.36, 65.32) 
-35.09 
(-98.84, 28.66) 
HIV-positive: not on ART 108 123.71 (30.1) 
HIV-positive: on ART 339 88.62 (13.8) 
HIV status unknown 25 11.14 (5.3) 
Total societal 
cost (2014 US$) 
HIV-negative 175 342.20 (34.0) 
96.76 
(17.11, 176.40) 
-141.95 
(-259.17, -24.73) 
HIV-positive: not on ART 108 546.61 (56.0) 
HIV-positive: on ART 339 404.65 (25.1) 
HIV status unknown 25 146.55 (21.3) 
*Admission EQ-
5D utility score 
(Zimbabwean 
tariff) 
HIV-negative 174 0.532 (0.02) 
-0.066 
(-0.114, -0.019) 
0.025 
(-0.033, 0.082) 
HIV-positive: not on ART 107 0.447 (0.03) 
HIV-positive: on ART 336 0.472 (0.02) 
HIV status unknown 23 0.454 (0.07) 
*Admission VAS 
score 
HIV-negative 174 55.1 (1.4) 
-3.2 
(-6.7, 0.2) 
-2.2 
(-7.0, 2.5) 
HIV-positive: not on ART 107 53.5 (2.1) 
HIV-positive: on ART 336 51.3 (1.1) 
HIV status unknown 23 53.9 (5.8) 
*Admission EQ-
5D utility score 
(UK tariff) 
HIV-negative 174 0.335 (0.03) 
-0.096 
(-0.165, -0.027) 
0.058 
(-0.022, 0.138) 
HIV-positive: not on ART 107 0.195 (0.03) 
HIV-positive: on ART 336 0.253 (0.02) 
HIV status unknown 23 0.280 (0.09) 
ART: Anti-retroviral treatment 715 
*Missing quality of life assessment – HIV negative: 1; HIV positive not on ART: 1; HIV positive on ART: 3; HIV status unknown: 2 716 
**Bootstrapped estimates of mean differences and 95%CI 717 
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Table 7: Multivariate analysis exploring relationship between HIV and ART status and mean total costs* 719 
 Total health provider cost 
(2014 US Dollars) 
Total direct non-medical and indirect cost 
(2014 US Dollars) 
Total societal cost 
(2014 US Dollars) 
Model 1 (n=605) 
Coef (95% CI) 
Model 2 (n=605) 
Coef (95% CI) 
Model 1 (n=605) 
Coef (95% CI) 
Model 2 (n=605) 
Coef (95% CI) 
Model 1 (n=605) 
Coef (95% CI) 
Model 2 (n=605) 
Coef (95% CI) 
HIV-positive: not on ART 
 
Ref Ref Ref Ref Ref Ref 
HIV-positive: on ART 
 
-87.06** 
(-163.07, -11.06) 
-51.04** 
(-94.86, -7.23) 
15.00 
(-25.27, 55.26) 
18.92 
(-23.65, 61.49) 
-70.98 
(-159.24, 17.27) 
-45.99 
(-99.88, 7.91) 
HIV-negative 
 
-140.43** 
(-219.41, -61.44) 
-45.60 
(-95.65, 4.45) 
-3.14 
(-56.17, 49.88) 
24.19 
(-36.02, 84.40) 
-128.65** 
(-224.49, -32.82) 
-34.76 
(-99.64, 30.11) 
HIV status unknown 
-279.86** 
(-361.81, -197.91) 
-146.93** 
(-202.61, -91.26) 
-60.23** 
(-111.56, -8.90) 
-9.10 
(-68.68, 50.49) 
-301.34** 
(-401.06, -201.63) 
-160.95** 
(-235.91, -85.99) 
ART: Anti-retroviral treatment 720 
Model 1: age and sex 721 
Model 2: additionally adjusted for primary medical diagnosis, marital status, educational attainment, income and wealth quintile 722 
*Findings from Generalized linear model with Poisson distribution and identity link function 723 
** p<0.05 724 
  725 
 726 
 727 
 728 
 729 
 730 
 731 
 732 
 733 
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Table 8: Multivariate analysis exploring relationship between HIV and ART status and health-related quality of life outcomes on 735 
admission* 736 
 Admission EQ-5D utility score 
(Zimbabwean tariff)  
Admission VAS score Admission EQ-5D utility score  
(UK tariff) 
Model 1 (n=605) 
Coef (95% CI) 
Model 2 (n=605) 
Coef (95% CI) 
Model 1 (n=605) 
Coef (95% CI) 
Model 2 (n=605) 
Coef (95% CI) 
Model 1 (n=605) 
Coef (95% CI) 
Model 2 (n=605) 
Coef (95% CI) 
HIV-positive: not on ART 
 
Ref Ref Ref Ref Ref Ref 
HIV-positive: on ART 
 
0.038 
(-0.019, 0.095) 
0.048 
(-0.011, 0.106) 
-0.99 
(-5.23, 3.25) 
-0.55 
(-4.80, 3.69) 
0.070 
(-0.013, 0.152) 
0.085 
(-0.001, 0.170) 
HIV-negative 
 
0.112** 
(0.051, 0.173) 
0.131** 
(0.064, 0.198) 
2.92 
(-1.63, 7.47) 
3.20 
(-1.60, 7.99) 
0.185** 
(0.095, 0.275) 
0.207** 
(0.108, 0.306) 
HIV status unknown 
0.076 
(-0.066, 0.218) 
0.092 
(-0.062, 0.245) 
7.85 
(-0.85, 16.54) 
9.47 
(-0.07, 19.01) 
0.147 
(-0.062, 0.356) 
0.160 
(-0.065, 0.385) 
Model 1: age and sex 737 
Model 2: additionally adjusted for primary medical diagnosis, marital status, educational attainment, income and wealth quintile 738 
*Findings from ordinary least squares estimator 739 
** p<0.05 740 
 741 
